Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

BACKGROUND: Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors synergistically increased the effectiveness of antiprogrammed cell death protein-1 (anti-PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Jun, Sakai, Hitomi, Tsurutani, Junji, Tanabe, Yuko, Masuda, Norikazu, Iwasa, Tsutomu, Takahashi, Masato, Futamura, Manabu, Matsumoto, Koji, Aogi, Kenjiro, Iwata, Hiroji, Hosonaga, Mari, Mukohara, Toru, Yoshimura, Kiyoshi, Imamura, Chiyo K, Miura, Sakiko, Yamochi, Toshiko, Kawabata, Hidetaka, Yasojima, Hiroyuki, Tomioka, Nobumoto, Yoshimura, Kenichi, Takano, Toshimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503337/
https://www.ncbi.nlm.nih.gov/pubmed/37709297
http://dx.doi.org/10.1136/jitc-2023-007126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503337/
https://www.ncbi.nlm.nih.gov/pubmed/37709297
http://dx.doi.org/10.1136/jitc-2023-007126

Ejemplares similares